Individuals Suffering From RLMS Now Have a New Drug Called Mavenclad That Can Help Alleviate Seizures

Lemtrada Stroke Lawsuit News

The FDA has approved a new drug for treating relapsing multiple sclerosis that has shown great promise and lesser side effects than Lemtrada or Tecfidera

Monday, April 1, 2019 - Multiple sclerosis affects young adults aged 20-40 and is more prevalent in women than men. Multiple sclerosis is an autoimmune disease affecting an individual's central nervous system disrupting the signal from the brain to certain other parts of the body.

Certain multiple sclerosis drugs on the market today carry boxed warnings that include sudden death, the most serious side effect of all. Individuals suffering from multiple sclerosis and the physicians that treat them should be aware that two drugs, in particular, have been brought to the attention of the USD Food and Drug Administration (FDA) and have been forced to add the serious side effect to their warning labels. National Lemtrada stroke attorneys are representing families and individuals that suffered from multiple sclerosis Lemtrada drug side effects.

One new and serious drug warning is that for Alemtuzumab which goes by the brand name Lemtrada. Since 2014, doctors have treated their patients suffering from relapsing multiple sclerosis (RLMS) with the drug if no other drug worked to control the patient's recurring multiple sclerosis seizures. An urgent safety alert was issued for Lemtrada shortly after the 13th case of a patient suffering a stroke was reported. Lemtrada causes the tissues of the major arteries such as the carotid artery to weaken causing fissures that trap blood. When enough blood coagulates and the clot breaks free, it can block blood flow in a smaller vessel resulting in a stroke. Lemtrada is manufactured by Genzyme, a subsidiary of the French pharmaceutical company Sanofi.

Later in 2014, the FDA issued another warning that a drug used to treat patients with RLMS has serious life-threatening side effects. A warning went out that Biogen Idec's Tecfidera (dimethyl fumarate) caused progressive multifocal leukoencephalopathy (PML) in a patient who later died. PML is a serious brain infection due to a compromised immune system. According to Neurology Advisor, "Symptoms of PML can include progressive weakness on one side of the body, vision problems, confusion, and cognitive changes, including changes in personality, thinking, memory, and orientation."

In response to the need for an alternative treatment of last resort for RLMS patients, the FDA approved "Mavenclad (cladribine) tablets to treat relapsing forms of multiple sclerosis (MS) in adults, to include relapsing-remitting disease and active secondary progressive disease." Like Lemtrada and Tecfidera, Mavenclad is recommended as a drug of last resort when other RLMS drugs have failed. Mavenclad has performed well in clinical trials consisting of over 1300 RLMS patients that have had at least one relapse episode within the last 12 months. According to the FDA, "Mavenclad significantly decreased the number of relapses experienced by these patients compared to placebo. Mavenclad also reduced the progression of disability compared to placebo." Mavenclad carries an FDA boxed warning due to the drug's potential to cause fetal harm. Women who are pregnant or will be sexually active and do not use birth control within 6 months from the date of staring Mavenclad should not use the drug.

More Recent Lemtrada Stroke Lawsuit News:

No-Cost, No-Obligation Lemtrada Lawsuit Case Review If You or a Loved One Suffered from Lemtrada Stroke Complications

OnderLaw, LLC is a St. Louis personal injury law firm handling serious injury and death claims across the country. Its mission is the pursuit of justice, no matter how complex the case or strenuous the effort. The Onder Law Firm has represented clients throughout the United States in pharmaceutical and medical device litigation such as Pradaxa, Lexapro and Yasmin/Yaz, where the firm's attorneys held significant leadership roles in the litigation, as well as Actos, DePuy, Risperdal and others. The Onder Law Firm has won more than $300 million in four talcum powder ovarian cancer lawsuits in St. Louis. Law firms throughout the nation often seek its experience and expertise on complex litigation.